A Phase II Investigation of Pembrolizumab (Keytruda) in Combination With Radiation and an Immune Modulatory Cocktail in Patients With Cervical and Uterine Cancer (PRIMMO Trial)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Feb 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Vitamin D (Primary) ; Aspirin; Cyclophosphamide; Lansoprazole
Indications Carcinoma; Cervical cancer; Endometrial cancer; Sarcoma; Uterine cancer
Focus Therapeutic Use
Acronyms PRIMMO

01 Feb 2023 Primary endpoint(Efficacy) has not been met according to Results published in the Cancer Immunology Immunotherapy.
01 Feb 2023 Results assessing efficacy of Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma published in the Cancer Immunology Immunotherapy
06 Sep 2021 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com